Table 1 Patient Characteristics

Gender

Female:

Male:

17 (41%)

24 (59%)

Lymphoma entity

LBCL:

MCL:

tFL:

35 (85%)

5 (12%)

1 (2%)

Ann Arbor Stage

I:

II:

III:

IV:

6 (15%)

6 (15%)

7 (17%)

22 (54%)

IPI

1:

2:

3:

4:

5:

7 (17%)

13 (32%)

13 (32%)

4 (10%)

4 (10%)

CAR T Product

Tisagenlecleucel:

Axicabtagene ciloleucel:

Brexucabtagene autoleucel:

Lisocabtagene maraleucel:

20 (58,8%)

13 (14,7%)

5 (23,5%)

3 (2,9%)

Bridging

Chemotherapy:

Radiation:

Immunotherapy:

Combined therapy:

No bridging:

21 (51%)

5 (12%)

2 (5%)

3 (7%)

10 (24%)

LDH (median)

Apheresis:

Prior Lymphodepletion:

343 U/L

277 U/L